grow risk alzheim pipelin
action make major chang earn estim revis
sale forecast elimin bace inhibitor alzheim diseas
previous factor beyond rais target
price potenti return reiter neutral
rate also add forecast
invest overview eisai share price gain news tie-up merck
develop merck antibodi keytruda eisai
proprietari anti-cancer lenvima contract eisai receiv total cash
revenu approx next five year eisai
project mileston one-tim receipt
howev eisai inabl defin likelihood success
alzheim diseas anti-amyloid-beta antibodi
aducanumab bace inhibitor lead share-
price instabl fail meet criteria success interim
analysi nonetheless although string develop failur
competitor bace inhibitor mechan eisai state
june clear first trial safeti toler result
final analysi phase trial releas around
augustw think investor expect much eisai share price
near term
increas depend
develop result aducanumab catalyst includ
expect boost lenvima success failur alzheim
valuat base ep previous
forward price-to-earnings forward price-to-earnings
valuat market price news lenvima allianc
current valuat seem high likelihood success
valuat metric
chang tp
number share mn
price month
price rel chart measur perform
topix close
spot exchang rate
suiss seek busi compani cover research report result investor awar
firm may conflict interest could affect object report investor consid report
singl factor make invest decis
price jun upsid rate neutral target price analyst fumiyoshi sakai
profit tax
issuanc retir stock
net chang cash
number share mn
net incom attribut
owner parent compani
cash equival
compani mention price
